Skip to main content

ADENOSINE-CLARIS, ADSINE (AFT Pharmaceuticals Pty Ltd)

Product name
ADENOSINE-CLARIS, ADSINE
Date registered
Evaluation commenced
Decision date
Approval time
141 working days (255)
Active ingredients
adenosine
Registration type
New generic medicine
Indication

Adenosine (solution for infusion) is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging in patients unable to exercise adequately.

Adenosine 6 mg/2 mL solution for injection is indicated for:

  • Therapeutic indications:
    • Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White syndrome).
  • Diagnostic indications:
    • Aid to diagnosis of broad or narrow QRS complex supraventricular tachycardias. Although adenosine 6 mg/2 mL is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of AV conduction helps diagnosis of atrial activity;
    • In this respect, adenosine should be used as an adjunct to, but not a replacement for, clinical and ECG observations. It should be used only when, despite all diagnostic attempts, doubt still persists;
    • Improved diagnostic sensitivity of intracavity electrophysiological investigations.

Help us improve the Therapeutic Goods Administration site